Open House Original Rebate Contracts 2026-02 - Ponatinib
Original notice title
Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-02 - Ponatinib
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated contract value or volume disclosed; potential low revenue.
Contract automatically ends upon patent expiry, shortening the effective period.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Apr 29, 2028
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Apr 2028
- Conclude discount agreements for Ponatinib with all eligible pharmaceutical entrepreneurs.
- Participants offer Ponatinib at discounted prices to the health insurance funds.
Show full summary
This is an Open House procedure for discount agreements (Rabattverträge) for the pharmaceutical product Ponatinib, organized by multiple German health insurance funds led by Techniker Krankenkasse. All eligible pharmaceutical entrepreneurs can join at any time during the contract period (May 2026 – April 2028). No competitive selection; contracts are concluded with all who meet the legal requirements. The estimated contract value is not disclosed, and no exclusivity is granted. The tender is not a public procurement under EU directives; disputes are subject to social court jurisdiction.
Risks
No estimated contract value or volume disclosed; potential low revenue.
Contract automatically ends upon patent expiry, shortening the effective period.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
- Hold valid marketing authorization for Ponatinib in Germany/EU/EEA.
Eligibility
- Submit self-declaration of eligibility and reliability (Anlage 4).
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Original Rebate Contracts 2026-02 - Ponatinib
Conclusion of pharmaceutical discount agreements for Ponatinib under §130c SGB V via an Open House procedure with uniform conditions; no individual negotiations; multiple participants allowed.
Location
Duration
Category
Award Criteria
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu Ponatinib im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Originale-Rabattverträge 2026-02 - Ponatinib
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu Ponatinib im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 15 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 178647-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated contract value or volume disclosed; potential low revenue.
Contract automatically ends upon patent expiry, shortening the effective period.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications